Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

Inclusion Criteria:

* Willing and able to provide written informed consent
* Male aged 18 years and above
* Histologically or cytologically confirmed adenocarcinoma of the prostate.
* Metastatic disease documented by positive bone scan or metastatic lesions other than liver or visceral metastasis on CT, MRI.
* Prostate cancer progression to previous castration treatment documented by PSA according to PCWG2 or radiographic progression according to modified RECIST criteria or bone scan progression
* Asymptomatic or mildly symptomatic from prostate cancer
* Surgically or medically castrated, with testosterone levels of \< 50 ng/dL (\< 2.0 nM).
* Previous anti-androgen therapy and progression after withdrawal.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Hemoglobin \>= 10.0 g/dL independent of transfusion
* Platelet count \>= 100,000/µL
* Serum albumin \>= 3.5 g/dL
* Serum creatinine \< 1.5 x ULN or a calculated creatinine clearance \>= 60 mL/min
* Serum potassium \>= 3.5 mmol/L
* Liver function: a. Serum bilirubin \< 1.5 x ULN (except for patients with documented Gilbert's disease) b. AST or ALT \< 2.5 x ULN
* Life expectancy of at least 6 months
* Patients who have partners of childbearing potential must be willing to use a method of birth control

Exclusion Criteria:

* Active infection or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
* Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone daily.
* Pathological finding consistent with small cell carcinoma of the prostate
* Liver or visceral organ metastasis
* Known brain metastasis
* Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1
* Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC
* Radiation therapy for treatment of the primary tumor within 6 weeks of Cycle 1, Day
* Radiation or radionuclide therapy for treatment of metastatic CRPC
* Previously treated with ketoconazole for prostate cancer for greater than 7 days
* Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1
* Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1
* Bicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of Cycle 1 Day 1
* Uncontrolled hypertension (systolic BP \>= 160 mmHg or diastolic BP \>= 95 mmHg).
* Active or symptomatic viral hepatitis or chronic liver disease
* History of pituitary or adrenal dysfunction
* Clinically significant heart disease
* Atrial Fibrillation, or other cardiac arrhythmia requiring therapy
* Other malignancy, except non-melanoma skin cancer, with a \>= 30% probability of recurrence within 24 months
* Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1
* Any condition which, in the opinion of the investigator, would preclude participation in this trial.